Pharmacophore Modeling
Pharmacophore-based Ligand Design and Virtual Screening · Also known as: pharmacophore pattern recognition, 3D pharmacophore
Pharmacophore modeling identifies the spatial arrangement of molecular features (hydrogen bond donors, acceptors, aromatic rings) that are essential for biological activity. Introduced by Gund in 1977, this ligand-based method creates a three-dimensional pattern that can screen chemical libraries and design new active compounds without requiring receptor structure.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
Pharmacophore modeling is valuable when you have multiple active compounds but lack a receptor crystal structure. It is particularly useful for scaffold hopping to discover chemically novel actives and for prioritizing compounds in large databases. Avoid relying exclusively on pharmacophores without independent validation when inactives contain features matching the pharmacophore.
Strengths & limitations
- Does not require receptor structure, enabling early-stage drug discovery
- Enables rapid scaffold hopping and chemical diversity exploration
- Computational efficiency allows screening of very large chemical libraries
- Provides interpretable spatial constraints for medicinal chemists
- Limited by the chemical diversity and representative nature of training actives
- Multiple competing pharmacophore hypotheses may emerge from diverse actives
- Pharmacophore patterns can be too permissive, leading to false positives
- Does not encode dynamic binding mechanisms or allosteric effects
Frequently asked
How many active compounds do I need to build a reliable pharmacophore?
A minimum of 3-5 structurally diverse actives is recommended to define essential features. Ideally, 10+ compounds with diverse scaffolds provide greater confidence in identifying truly conserved pharmacophoric features versus incidental similarities.
How do I validate that my pharmacophore hypothesis is predictive?
Partition your active set into training (70-80%) and test (20-30%) subsets. Build the pharmacophore on training actives and measure its ability to predict and rank-order test actives. Also evaluate enrichment against known inactives from your database.
Can a single pharmacophore represent multiple binding modes of the same target?
Not reliably. If your actives bind via distinct mechanisms, build separate pharmacophores for each mode or use ensemble approaches. Single pharmacophores work best when actives share a common binding orientation.
Sources
- Wermuth, C. G., Ganellin, C. R., Lindberg, P., & Mitscher, L. A. (1998). Glossary of terms used in medicinal chemistry. Pure and Applied Chemistry, 70(5), 1129-1143. DOI: 10.1351/pac199870051129 ↗
- Ohno, K. & Ueda, Y. (2006). Modern photochemistry of organic compounds. Wiley & Sons. link ↗
- Leung, S. C., Bodkin, M., von Delft, F., & Morris, G. M. (2012). SiteMap: a tool for identifying and characterizing binding sites in protein structures. Journal of Chemical Information and Modeling, 52(11), 3008-3020. link ↗
How to cite this page
ScholarGate. (2026, June 3). Pharmacophore-based Ligand Design and Virtual Screening. ScholarGate. https://scholargate.app/en/bioinformatics/pharmacophore-modeling
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Homology ModelingBioinformatics↔ compare
- Molecular DockingBioinformatics↔ compare
- QSARBioinformatics↔ compare